within Pharmacolibrary.Drugs.ATC.B;

model B02BD01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 3.7 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 25 / 1000000,
    adminCount     = 1,
    Vd             = 4e-05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>This combination is a prothrombin complex concentrate (PCC), comprised of human blood plasma-derived coagulation factors II, VII, IX, and X, typically used for the treatment and prevention of bleeding in patients with deficiency of multiple vitamin K-dependent clotting factors, such as in cases of warfarin reversal or hereditary deficiency. Prothrombin complex concentrates are still approved and in clinical use, such as in urgent reversal of anticoagulation.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are variably reported for individual factors, but specific PK for the 4-factor PCC combination limited. Data below are representative values estimated for adult populations from published summaries and product monographs.</p><h4>References</h4><ol><li><p>Honickel, M, et al., &amp; Grottke, O (2016). Therapy with activated prothrombin complex concentrate is effective in reducing dabigatran-associated blood loss in a porcine polytrauma model. <i>Thrombosis and haemostasis</i> 115(2) 271â€“284. DOI:<a href=&quot;https://doi.org/10.1160/TH15-03-0266&quot;>10.1160/TH15-03-0266</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26333775/&quot;>https://pubmed.ncbi.nlm.nih.gov/26333775</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end B02BD01;
